Jimin Health announces progress in share repurchase program

Zhejiang Chimin Pharmaceutical (SSE:603222) announced the progress of its share repurchase program via centralized bidding transactions. As of May 30, 2025, the company had cumulatively repurchased 2,005,500 shares, representing 0.3819% of the total share capital, with prices ranging from CNY 5.87 to CNY 6.13 per share and a total expenditure of CNY 12,088,967.50 (excluding transaction costs). The repurchase program, approved on March 28, 2025, aims to repurchase shares worth between CNY 10,000,000 and CNY 20,000,000 for employee stock ownership plans or equity incentives, or to maintain the company's value. The company will continue to implement the repurchase plan according to market conditions and disclose information in a timely manner.